NeoGenomics gives upward Q3 revision, shares rise

NeoGenomics (NEO) revises Q3 guidance in the right direction, lifting EPS and revenue expectations to $0.01-0.02 (from $0-0.01) and $16.6-16.9M (from $15.8-16.4M) respectively.

Sales during the quarter have been robust and "continued to accelerate in September," CEO Doug VanOort says. (PR)

NEO +5% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs